Podcasts about Polycythemia vera

Highlights from the PER® CME activity "Cases and Conversations: Adopting New Treatment Strategies in Polycythemia Vera and Essential Thrombocythemia" — this podcast is not certified for credit. To participate in the full accredited activity and earn CME credit, use the link below.In this podcast, experts Gabriela Hobbs, MD; Rami Komrokji, MD; and Douglas A. Tremblay, MD; discuss the management of low-risk polycythemia vera (PV) based on the latest data.Earn CME credit by completing the full accredited activity (available through June 30, 2027): https://www.gotoper.com/courses/cases-and-conversations-adopting-new-treatment-strategies-in-polycythemia-vera-and-essential-thrombocythemia-fvrlThis podcast, including the narration, was developed by PER® (Physicians' Education Resource®, LLC) editorial staff from the full online CME activity developed with these faculty. The narration was voiced by a PER staff member or by an AI tool. The podcast contains no product advertising. The full activity is supported by an educational grant from Incyte Corporation.This content is for educational purposes only and is not a substitute for the independent clinical judgment of a health care professional. Faculty may discuss investigational or off-label uses; consult prescribing information for any products discussed.

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we're diving into a series of compelling stories that showcase the dynamic nature of this industry. In a landmark development, Vertex Pharmaceuticals has made headlines with its acquisition of Crinetics Pharmaceuticals for a staggering $10 billion. This move marks Vertex's strategic expansion into the endocrine disease sector, a significant shift from its traditional focus on cystic fibrosis. Crinetics' innovative approach to treating rare endocrine disorders will allow Vertex to address unmet needs in this area, highlighting a broader industry trend where mergers and acquisitions serve as key strategies for adapting to the evolving scientific landscape and patient demands. While Vertex makes bold moves, Kalohexis is preparing for a confidential initial public offering (IPO), focusing on treatments based on the melanocortin system for obesity and cancer cachexia. The melanocortin system is crucial in regulating energy homeostasis and inflammation, making it a promising target for therapeutic interventions. This development underscores the growing interest in peptide-based therapies and innovative scientific approaches to address complex metabolic disorders, further emphasizing the industry's shift towards tackling significant health challenges such as obesity. Clinical trials continue to be at the forefront of medical advancements. Compass Pathways has reported promising Phase III trial results for COMP360, its psilocybin-based therapy for treatment-resistant depression. These findings indicate a potential breakthrough in psychedelic therapy, offering new hope for patients who haven't benefited from existing antidepressant treatments. The exploration of psychedelics in mental health treatment represents a paradigm shift that could introduce novel therapeutic options and significantly impact patient care. Turning to regulatory news, AbbVie's Tepkinly (epcoritamab) has received European Commission approval for treating relapsed or refractory follicular lymphoma. This approval is based on robust Phase III data, underscoring the potential of bispecific antibodies as effective cancer therapies. Similarly, PharmaEssentia's Besremi (ropeginterferon alfa-2b) has obtained Health Canada approval for polycythemia vera treatment, highlighting the continued relevance of protein and interferon therapies in managing myeloproliferative neoplasms. In business development news, Novo Nordisk and Vivani Medical have partnered to develop an ultra-long-acting semaglutide implant for chronic weight management. This collaboration showcases advancements in drug delivery systems aimed at improving patient compliance and therapeutic outcomes. Meanwhile, Boehringer Ingelheim's licensing agreement with Prime Vector Technologies involves harnessing viral vectors for cancer vaccine development, emphasizing ongoing efforts to innovate within oncology. Despite these advancements, challenges persist within the industry. Notably, Bristol Myers Squibb's Krazati (adagrasib) failed its Phase III confirmatory trial in metastatic colorectal cancer with KRAS G12C mutations. This outcome highlights the complexities involved in developing targeted cancer therapies and underscores the need for continued innovation and exploration of combination treatments. The financial landscape also reflects strategic adjustments with Regeneron Pharmaceuticals reporting a $127 million charge impacting its earnings due to an in-process research and development expense. Additionally, Novartis is undergoing organizational restructuring with workforce reductions aimed at cost management within large pharmaceutical enterprises. On another front, China's recent approval of the world's first CAR-T therapy for solid tumors marks a significant leap forward from its traditional success in hematological malignancies. This development highlights the potential for CAR-T therapies to address complex challenges posed by solid tumors and could have profound implications for global cancer treatment paradigms. AstraZeneca's partnership with CSPC Pharmaceutical represents another strategic collaboration aimed at co-developing kidney disease drugs, reflecting Western pharmaceutical companies' efforts to leverage Chinese biotechnological capabilities. As companies navigate these complexities through strategic acquisitions, partnerships, and groundbreaking research, their ability to adapt will be crucial in shaping future patient care and therapeutic landscapes. The pharmaceutical and biotech industries remain at the forefront of scientific advancement, continually seeking solutions to complex medical needs while adapting to an ever-evolving global landscape.Support the show

In this podcast episode, Ciro Rinaldi MD, PhD, and Alessandro M. Vannucchi, MD, discuss contemporary management of essential thrombocythemia (ET) and polycythemia vera (PV), as well as novel investigational approaches, including the following: Overview of current treatment paradigms for PV and ET Importance of shared decision-making and patient communication in determining treatment Current therapeutic areas of need in ET and PV Emerging investigational therapeutics Presenters: Ciro Rinaldi MD, PhD Chief Medical Officer, United Lincolnshire Teaching Hospital Honorary Professor of Haematology, University of Lincoln Honorary Professor De Montfort University Dubai Consultant Haematologist Lincoln, United Kingdom Alessandro M. Vannucchi, MD Professor of Hematology University of Florence Director of Hematology Department Director of Oncology Department Azienda Ospedaliera Universitaria Careggi Florence, Italy Content based on an online CME program supported by an educational grant from Merck. Link to full program:https://bit.ly/4u09lKd Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode, hear Anthony Hunter, MD and Douglas Tremblay, MD discuss the various presentations of thrombotic events in patients with PV or ET including how thrombotic events may lead to diagnosis:  PV and ET increase the risk of both arterial and venous thrombotic events  Unusual thrombotic events  Thrombosis as initial presentation for MPN Case presentations Brief overview of thrombosis management Program faculty: Anthony M. Hunter, MD Associate Professor, Department of Hematology and Medical Oncology Leader, Myeloproliferative Neoplasm Program Medical Director, Rollins Immediate Care Center Winship Cancer Institute of Emory University, Leukemia Group Atlanta, Georgia Douglas Tremblay, MD Associate Professor of Medicine Division of Hematology/Oncology Tisch Cancer Institute Icahn School of Medicine at Mount Sinai New York, New York Link to obtain CME/CE credit: https://bit.ly/4egx4Rf Link to program page: https://bit.ly/3OPSASy Get access to all of our new podcasts by subscribing to the Decera Clinical Education Oncology Podcast on Apple Podcasts, YouTube Music, or Spotify. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this podcast episode, Ciro Rinaldi, MD, PhD, and Alessandro M. Vannucchi, MD, as they discuss contemporary topics in diagnosing essential thrombocythemia (ET) and polycythemia vera (PV), including: Overview of diagnostic criteria for PV and ET Importance of bone marrow biopsy Degree of suspicion of PV/ET in patients presenting with thrombotic events Pearls of wisdom in diagnosis Presenters:  Ciro Rinaldi, MD, PhD Chief Medical Officer, United Lincolnshire Teaching Hospital Honorary Professor of Haematology, University of Lincoln Honorary Professor De Montfort University Dubai Consultant Haematologist Lincoln, United Kingdom Alessandro M. Vannucchi, MD Full Professor of Hematology University of Florence Director of Hematology Department Director of Oncology Department Azienda Ospedaliera Universitaria Careggi Florence, Italy Content based on an online CME program supported by an educational grant from Merck. Link to full program: https://bit.ly/4u09lKd Get access to all our new podcasts by subscribing to the Decera Clinical Education Oncology Podcast on Apple Podcasts, YouTube Music, or Spotify. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Dinesh Patel, PhD, CEO of Protagonist Therapeutics, discusses the New Drug Application (NDA) submission to the US Food and Drug Administration (FDA) for rusfertide to treat adults with polycythemia vera (PV).PV is characterized by excess red blood cells in the bloodstream, increasing the risk for blood clots. Most cases of PV are acquired and occur more frequently in men than in women. The condition has been associated with genetic changes in the JAK2 and TET2 genes. Rusfertide is an investigational first-in-class subcutaneously administered hepcidin mimetic peptide designed to regulate iron homeostasis and red blood cell production to control hematocrit levels in patients with PV.The NDA submission is based on positive 32-week primary analysis and 52-week results from the phase 3, global, randomized, placebo-controlled VERIFY clinical trial (NCT05210790). In this study, patients receiving rusfertide plus standard of care therapy demonstrated a substantially higher response rate compared to placebo plus standard of care, including durable hematocrit control, a reduction in phlebotomy requirements and improvement in pre-specified patient reported outcome endpoints.Rusfertide has received Breakthrough Therapy Designation, Orphan Drug Designation, and Fast Track Designation from the FDA.

In this episode, hear Joan How, MD and Pankit Vachhani, MD share their insights on the importance of shared decision-making (SDM) for patients with polycythemia vera (PV) or essential thrombocythemia (ET) including: Personal insights and examples of the process of SDM with patients with PV or ETHow nuances of managing PV/ET influence SDMIndividualizing the process of SDMBarriers to effective SDMEducational resources for patients with PV, ET, or MPNsWorking with a team to incorporate SDM into clinical practiceProgram faculty:Joan How, MDScientific and Medical ConsultantClinical Chief of HematologyBrigham and Women's Faulkner HospitalAssociate PhysicianBrigham and Women's HospitalAssistant Professor in MedicineHarvard Medical SchoolBoston, MassachusettsPankit Vachhani, MDAssociate Professor of MedicineDivision of Hematology and OncologyUniversity of Alabama at BirminghamO'Neal Comprehensive Cancer Center at the UABBirmingham, AlabamaLink to obtain CME/CE credit:https://bit.ly/3ZtxWJmLink to program page: https://bit.ly/3YQKlHbGet access to all of our new podcasts by subscribing to the CCO Infectious Disease Podcast on Apple Podcasts, YouTube Music, Podcasts, or Spotify. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Host: Hallie Blevins, PhD. Early resistance to hydroxyurea in patients with polycythemia vera (PV) is associated with higher risks of thromboembolic complications, disease progression, and mortality. The PV-AIM study applied machine learning to real-world data and identified simple lab-based predictors that stratify patients by risk, and these findings were later validated in the HU-F-AIM trial. Hear from ReachMD's Dr. Hallie Blevins as she dives into the results and explains implications for optimized therapy and improved long-term outcomes.

Host: Hallie Blevins, PhD. Early resistance to hydroxyurea in patients with polycythemia vera (PV) is associated with higher risks of thromboembolic complications, disease progression, and mortality. The PV-AIM study applied machine learning to real-world data and identified simple lab-based predictors that stratify patients by risk, and these findings were later validated in the HU-F-AIM trial. Hear from ReachMD's Dr. Hallie Blevins as she dives into the results and explains implications for optimized therapy and improved long-term outcomes.

Host: Hallie Blevins, PhD. Early resistance to hydroxyurea in patients with polycythemia vera (PV) is associated with higher risks of thromboembolic complications, disease progression, and mortality. The PV-AIM study applied machine learning to real-world data and identified simple lab-based predictors that stratify patients by risk, and these findings were later validated in the HU-F-AIM trial. Hear from ReachMD's Dr. Hallie Blevins as she dives into the results and explains implications for optimized therapy and improved long-term outcomes.

In this episode, we review the high-yield topic of⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ ⁠Polycythemia Vera ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠from the Oncology section.Follow⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Medbullets⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ on social media:Facebook: www.facebook.com/medbulletsInstagram: www.instagram.com/medbulletsofficialTwitter: www.twitter.com/medbullets

A late-breaking abstract presented at the 2025 American Society of Clinical Oncology Annual Meeting (LBA3) showed that rusfertide significantly increased hematocrit control and improved symptoms for patients with polycythemia vera, a chronic leukemia. “We thought if we could use our understanding of iron regulation, then we could change the game a little bit,” said Andrew Kuykendall, MD, assistant member in the Department of Malignant Hematology at the Moffitt Cancer Center in Tampa, Florida. He told Robert A. Figlin, MD, the interim director of Cedars-Sinai Cancer in Los Angeles and Steven Spielberg Family Chair in Hematology-Oncology, about the rationale behind the trial, broke down key findings, and shared what comes next in this area of research. “I think it is very important that we continue to follow these patients. And this is an ongoing trial that has a part two to it, which is a long-term safety assessment period,” he explained.

Drs. Bose and Pemmaraju review secondary myelofibrosis arising from polycythemia vera or essential thrombocythemia and how it differs from primary myelofibrosis that develops de novo.

This week's episode will be re-discussing one of the myeloproliferative neoplasms, Polycythemia Vera (PV). We will go over the important details on the diagnosis, risk stratification for thrombus and treatment.

In this episode, we discussed the diagnosis and management of polycythemia vera with Dr. Aaron T. Gerds. Here are the shownotes with the key studies discussed: 1.     MIPS PV scoring systemhttps://pubmed.ncbi.nlm.nih.gov/31945802/2.     REVEAL studyhttps://ashpublications.org/blood/article/143/16/1646/506717/Association-between-elevated-white-blood-cell3.     MAJIC PV studyhttps://ascopubs.org/doi/10.1200/JCO.22.01935?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%200pubmed4.     Cyto-PV Studyhttps://www.nejm.org/doi/full/10.1056/NEJMoa12085005.     PROUD-PV and CONTINUATION-PV trialshttps://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(19)30236-4/abstract6.     RESPONSE clinical trialhttps://www.nejm.org/doi/full/10.1056/NEJMoa14090027.     Rusferitide in PVhttps://www.nejm.org/doi/10.1056/NEJMoa2308809?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%200pubmed

In this episode, listen to Dr Brady L. Stein share his clinical insights and takeaways on new data for myeloproliferative neoplasms (MPNs) presented at the 2024 ASCO Annual Meeting and the EHA 2024 Congress including:Long-term survival adjusted for treatment crossover in patients with myelofibrosis (MF) treated with momelotinib vs danazol in the MOMENTUM trialEfficacy of pacritinib in patients with MF who have both thrombocytopenia and anemiaUpdated safety and efficacy data from the phase III MANIFEST-2 study of pelabresib in combination with ruxolitinib for JAK inhibitor–naive MFImpact of spleen volume on post-allogenic hematopoietic transplant outcomes in patients with MF: utility of 3D volumetrics in splenomegalyProgression to MF in patients with essential thrombocythemia: an analysis from the prospective MOST studyJAK2V617F molecular response correlates with event-free survival in a patient population with early polycythemia veraPhase III TRANSFORM-1 study: efficacy and safety of navitoclax combined with ruxolitinib vs ruxolitinib plus placebo in patients with untreated MFPatient characteristics, treatment patterns, and health outcomes in a real-world population of patients with MF treated with fedratinib Program faculty:Brady L. Stein, MD, MHSProfessor of MedicineDepartment of Hematology/OncologyNorthwestern University Feinberg School of MedicineChicago, Illinois Resources:To download the slides associated with this podcast discussion, please visit the program page.

On this special episode of the BloodStream Podcast, we explore interferons in the treatment of polycythemia vera (or PV). This episode is brought to you by PharmaEssentia. If you'd like to learn more about polycythemia vera, check out our sister show PV Pod: Stories from the Marrow (brought to you by BloodStream Media and PharmaEssentia).    Connect with BloodStream Media: BloodStreamMedia.com BloodStream on Facebook  BloodStream on Twitter

Dr Naveen Pemmaraju from The University of Texas MD Anderson Cancer Center in Houston discusses updated findings from ASH 2023 on management approaches for myelofibrosis and polycythemia vera, moderated by Dr Neil Love. Produced by Research To Practice. CME information and select publications here (https://www.researchtopractice.com/OncologyTodayPostASH24/MPN).

Dr. Harris speaks on PV

Live Nursing Review with Regina MSN, RN! Every Monday & Wednesday we are live. LIKE, FOLLOW, & SUB @ReMarNurse for more.     ► Create Free V2 Account - http://www.ReMarNurse.com ► Get Quick Facts Next Gen - https://bit.ly/QF-NGN ► Subscribe Now - http://bit.ly/ReMar-Subscription ► GET THE PODCAST: https://remarnurse.podbean.com/ ► WATCH LESSONS: http://bit.ly/ReMarNCLEXLectures/ ► FOLLOW ReMar on Instagram: https://www.instagram.com/ReMarNurse/ ► LIKE ReMar on Facebook: https://www.facebook.com/ReMarReview/   Quick Facts for NCLEX Next Gen Study Guide here - https://bit.ly/QF-NGN Study with Professor Regina MSN, RN every Monday as you prepare for NCLEX Next Gen.   ReMar Review features weekly NCLEX review questions and lectures from Regina M. Callion MSN, RN. ReMar is the #1 content-based NCLEX review and has helped thousands of repeat testers pass NCLEX with a 99.2% student success rate! ReMar focuses on 100% core nursing content and as a result, has the best review to help nursing students to pass boards - fast!

This week we bring you a two-in-one! We cover polycythemia vera and essential thrombocytosis. Written by: Dr. RuiQi (Richard) Chen (Internal Medicine Resident) Reviewed by: Dr. Hassan Sibai (Hematology) and Dr. Christopher Langlois (GIM)Support the show

In this week's podcast, "Tyre'd but not out" we are very pleased to have a very special guest Keith Ambrose.Kieth is a local (to us) very successful businessman, owner of the company "Treadfirst" with a number of outlets across East Anglia in the United Kingdom.There are over 200 different types of Cancer worldwide and today we discuss with Keith one very rare Cancer known as "Polycythemia Vera"Keith openly and honestly tells of his pre-diagnosis conditions, how for three years he struggled to get to a point when a full and complete diagnosis was eventually made, and his procedures and ongoing treatment to the present day.This truly is a remarkable story and such an addictive listen, an insight into one of the rarest Cancers today of which we still know very little.Keith's Cancer study made a new ground-breaking discovery in the understanding of Polycythemia Vera which astounded the leading Professor in this field.Note:  We appreciate the word Tyre'd in the title is spelled incorrectly, but it relates to Keith's business which involves Tyres.Check out our new website at www.whostomanddick.com

This week's episode will be focusing on another one of the myeloproliferative neoplasms (MPN): Polycythemia Vera (PV). We will go over the important details on the diagnosis, risk stratification, and treatment.

In this week's episode, we'll discuss new evidence on the critical role of hepcidin, the master regulator of iron metabolism, in the pathogenesis of polycythemia vera. Next, costimulatory molecules regulate mechanisms of CAR T cell dysfunction. Finally, we'll discuss how TREM2 is a novel receptor for IL-34, promoting differentiation of normal and leukemic myeloid cells. 

Dr. Barbara Abernathy is the President and CEO of The Pediatric Oncology Support Team, (POST) serving South Florida.  She was already working at POST, helping pediatric cancer patients and their families, when she herself was diagnosed with Polycythemia Vera, a blood cancer, in 1996.  She kept her diagnosis to herself.In 2013, Barb's disease morphed into AML, and she was in urgent need of a bone marrow transplant.  A match, a young man in Germany, was found.   Barb's intimate knowledge of cancer treatment proved both blessing and a curse.  She quite honestly was more afraid of Graft Versus Host Disease (GVHD) than she was of dying from the transplant.After her bone marrow transplant at Moffitt Cancer Center in Tampa, she dealt with acute GVHD of the eyes, gastrointestinal system (GI  system), skin, and liver.  Her acute GVHD rolled right into chronic. Her existing symptoms persisted, including hair loss due to alopecia.  People assume she's still in treatment because of the hair loss.Barb is very honest about the challenges of living with GVHD.  Not being able to sweat in Florida requires a lot of planning and care.  There was also the isolation during the pandemic.  Fatigue is also an issue.  Sometimes it's challenging just to keep the house clean.  This affects her desire to have friends over; it's not that she doesn't want to see them!Her personal experience has led to greater connections with her patients.  She's walked the walk and can talk the talk.  Barb talks about the importance of advocating for yourself or your child with your medical team. We also spend some time on how friends and family can help.  Sometimes it is as easy as changing the plan to better accommodate the survivor--maybe a breakfast date instead of a dinner date.  It's important to LISTEN and not just offer something you  think they need.  Peer support is also key. Between patients and her own journey, Barb has many years of experience with GVHD.  She talks about the new advances in therapy, how far we've come, and how it's given her hope for future treatment.Barb's nonprofit, Pediatric Oncology Support Team (POST) Website: https://postfl.org/Other ResourcesNational Bone Marrow Transplant Link - (800) LINK-BMT, or (800) 546-5268.nbmtLINK Website: https://www.nbmtlink.org/nbmtLINK Facebook Page:  https://www.facebook.com/nbmtLINKnbmtLINK YouTube Page can be found by clicking here.Thank you to this season's sponsors:Supported by Pharmacyclics, an AbbVie Company (https://www.pharmacyclics.com/) and Janssen Biotech, Inc. (https://www.janssen.com/)Incyte: https://www.incyte.com/

In this podcast episode, Prithviraj Bose, MD, and Andrew Kuykendall, MD, discuss their contemporary approaches to the treatment of patients with essential thrombocythemia. The topics covered include:When to use cytoreduction therapies and which therapies to use in low-risk patientsType 1 and type 2 CALR mutations and addressing patient concerns with data from sequencing reportsExperts' thoughts on therapy options in higher-risk patientsPresenters:Prithviraj Bose, MDAssociate ProfessorDivision of Cancer MedicineDepartment of LeukemiaThe University of TexasMD Anderson Cancer CenterHouston, TexasAndrew Kuykendall, MDAssistant Professor Department of Oncologic SciencesUniversity of South FloridaAssistant MemberMalignant HematologyH. Lee Moffitt Cancer CenterTampa, Florida Content for this program was supported by educational grants from GSK, Incyte Corporation, and PharmaEssentia Corp.Link to the full program, including downloadable slides and an on-demand webcast from the live event:bit.ly/3XF3cSF

In this podcast episode, Raajit Rampal, MD, PhD, and Brady L. Stein, MD, MHS, discuss their contemporary approaches to the treatment of patients with polycythemia vera. The topics covered include:Patient presentation and goals of frontline therapyConsiderations for second-line therapy in the setting of treatment intoleranceExperts' thoughts on the potential of early intervention to alter disease progressionPresenters:Raajit Rampal, MD, PhDAssociate MemberAssociate Attending PhysicianLeukemia ServiceDepartment of MedicineMemorial Sloan Kettering Cancer CenterNew York, New YorkBrady L. Stein, MD, MHSProfessor of MedicineDepartment of Hematology/OncologyNorthwestern University Feinberg School of MedicineChicago, IllinoisContent for this program was supported by educational grants from GSK, Incyte Corporation, and PharmaEssentia Corp.Link to the full program, including downloadable slides and an on-demand webcast from the live event:https://bit.ly/3X3x6jX

Join the #1 community of nursing students on the planet with 12,000+ students studying now inside of the NCLEX Virtual Trainer review on sale now at http://www.ReMarNurse.com   Your NCLEX RN & LPN Study Tools:  ► Get NCLEX Virtual Trainer: http://www.ReMarNurse.com/NCLEXVT ► Get the Question Bank: http://www.ReMarNurse.com/NCLEXQBank ► Get Quick Facts for NCLEX: http://bit.ly/QuickFactsNCLEX Get MORE from Regina MSN, RN: ► WATCH MORE: http://bit.ly/PassNCLEXPlayList/ ► GET THE PODCAST: https://remarnurse.podbean.com/ ► WATCH LESSONS: http://bit.ly/ReMarNCLEXLectures/ ► FOLLOW ReMar on Instagram: https://www.instagram.com/ReMarNurse/ ► LIKE ReMar on Facebook: https://www.facebook.com/ReMarReview/   ReMar Review features weekly NCLEX review questions and lectures from Regina M. Callion MSN, RN.  ReMar is the #1 content-based NCLEX review and has helped thousands of repeat-testers pass NCLEX with a 99.2% student success rate!   ReMar focuses on 100% core nursing content and as a result, has the best review to help nursing students pass boards - fast!

Welcome back to our weekend Cabral HouseCall shows! This is where we answer our community's wellness, weight loss, and anti-aging questions to help people get back on track! Check out today's questions:    Zoe: Hi there! Just listened your episode “how to cure constipation” as I am constipated right now. You mentioned that you would recommend an international cleanse. I didn't see the brand in the show notes. Could you please tell me which brand you recommend for that? Also I have already purchased the 21 day detox. Should I do a intensional cleanse first and then detox? Or is it okay to just start with the detox? I am getting my hormonal birth control out on the 22nd so I was planning on starting the detox on the day of removal or next day.   Anonymous: Dr. Cabral, by the time you answer this, I will have completed the CBO protocol and likely be continuing through the CBO Finisher. I am currently beginning month 3 of the CBO and have a need for more improvements in my constipation/trapped gas symptoms. I have been very diligent, and followed the protocol exactly as recommended. I tried the intestinal cleanse on week 6 and experienced the constipation and lack of motility in over two years, and I took the binder and 4 capsules 3x per day for 5 days with only one bowel movement. If this protocol does not provide any improvements, where do I go from here? What testing do you recommend? (I did the HMTA and Stool Test leading into the CBO). Thank you!!   Samantha: Hi Dr. Cabral, Thank you for all that you do! I would love your insight. I'm a 30-year-old woman from New York. I recently had surgery on my right side Bartholin gland. I had an allergic reaction to either the anesthesia or intravenous antibiotics they gave me during the procedure. I'm seeing an allergist in a few weeks to figure that out. I had dermatitis that spread all over my torso, chest, arms, and back; it was pretty severe. A dermatologist prescribed me a ten-day taper protocol of Prednisone (which was really intense!). At the time of writing this, I'm done with the Prednisone and the bumps from the allergic reaction are gone, but I'm still SO itchy and I'm breaking out in hives. The itching feels like it's coming from the inside out if that makes sense. Actually scratching the area doesn't provide relief. I've been diagnosed with mast cell activation syndrome and I'm listening to your previous podcasts about it now. I've also been taking allergy medication and eating a low histamine diet. This combination provides very slight relief. I feel hopeless and want to feel like myself again. Thank you for any guidance that you may have. With Gratitude, Samantha   Stefanie: Hi Dr. Cabral, You are truly amazing! I love all that you do and am so appreciated for finding equi.life and these podcasts! You are a blessing I have had hypothyroidism and addison's disease for 5 years. Recently my doctor discovered that I also have Polythemia Vera. In your experience have you seen all of these diseases to be related? I'm trying to find the right direction on how to naturally lower my red blood cell count without having to take blood medication to lower this. Have you worked with patients with polythemia vera? I would love any advice on where to begin healing this blood disorder.   Cassie: Hi Dr Cabral. Thank you for all you do for everyone here. It's appreciate by so many of us! I have this “anxiety rash” is what my doctor labeled it as, but it happens with any heightened emotion, happy or sad and when I'm nervous. It starts on my neck and moves to my chest and when it's really bad it goes to my arms. Splotches on my face can appear too and my cheeks are always sort of red anyways. Sometimes a trigger is as simple as a customer at work complimenting me, and I feel it happening, which I don't really understand. Or being excited about something. Not all the time, but sometimes it can feel like a rush of adrenaline. It's come to the point where I feel uncomfortable in my own skin and I've hidden it for years by not wearing shirts or anything that goes below my collar bones or people always ask what's wrong. I'm getting married this summer and it makes me nervous I'm going to be a red mess because I know I'll feeling all the emotions that day. Doctors have just thrown anxiety meds at me, and that is not what I'm looking for. I am a very active person, exercise a lot and eat pretty healthy, I have noticed the healthier I eat the better it is but I can't figure out triggers with food. Any advice is so greatly appreciated! Thank you, Cassie   Marleen: My bloodwork showed high B12 but I don't supplement how is this possible?   Thank you for tuning into today's Cabral HouseCall and be sure to check back tomorrow where we answer more of our community's questions!    - - - Show Notes and Resources: StephenCabral.com/2346 - - - Get a FREE Copy of Dr. Cabral's Book: The Rain Barrel Effect - - - Join the Community & Get Your Questions Answered: CabralSupportGroup.com - - - Dr. Cabral's Most Popular At-Home Lab Tests: > Complete Minerals & Metals Test (Test for mineral imbalances & heavy metal toxicity) - - - > Complete Candida, Metabolic & Vitamins Test (Test for 75 biomarkers including yeast & bacterial gut overgrowth, as well as vitamin levels) - - - > Complete Stress, Mood & Metabolism Test (Discover your complete thyroid, adrenal, hormone, vitamin D & insulin levels) - - - > Complete Food Sensitivity Test (Find out your hidden food sensitivities) - - - > Complete Omega-3 & Inflammation Test (Discover your levels of inflammation related to your omega-6 to omega-3 levels) - - - Get Your Question Answered On An Upcoming HouseCall: StephenCabral.com/askcabral - - - Would You Take 30 Seconds To Rate & Review The Cabral Concept? The best way to help me spread our mission of true natural health is to pass on the good word, and I read and appreciate every review!

This is the third installment of the Cancer History Project's series in honor of Cancer Survivors Month. Dr. Deborah Doroshow, Cancer History Project guest editor during the month of June, conducted the following interview with Dave Boule, who was diagnosed with polycythemia vera in 2006. Soon after Boule was diagnosed, he had a hunch that there were better treatment options than the phlebotomies his New York doctor was treating him with. Boule did his research, and stumbled upon studies written by Dr. Richard T. Silver, who is now director emeritus of the Richard T. Silver MD Myeloproliferative Neoplasms Center. Silver's studies demonstrated that interferon would be the best treatment for his disease. Since then, Boule has undergone successful treatment with interferon, which he still takes today. His advice to newly diagnosed patients with myeloproliferative neoplasms: seek out a doctor who specializes in the disease. A transcript of this episode is available here: https://cancerhistoryproject.com/article/dave-boule-confronted-polycythemia-vera-with-an-accountants-consistency/

Jeremy Moberly was diagnosed with Polycythemia Vera in 2018 and is statistically on the younger end of the typical MPN Patient. We talk with Jeremy about his initial reaction to the diagnosis and how he has changed his life to live in this New World.We also talk about the importance of diet and exercise as well as how a thirty something MPN Patient deals with dating and sharing his situation with potential life partners. 

In this episode, we review the high-yield topic of Polycythemia Vera from the Oncology section. Follow Medbullets on social media: Facebook: www.facebook.com/medbullets Instagram: www.instagram.com/medbulletsofficial Twitter: www.twitter.com/medbulletsIn this episode --- Send in a voice message: https://anchor.fm/medbulletsstep1/message

Anne Lynn Su Chang, MD interviewed by Vesna Petronic-Rosic, MD, FAAD

Joanne was diagnosed with Polycythemia vera in 2012. She shares her experience with her diagnosis, the support she received from local groups and how it has changed her life.

Join us as we speak with David Wallace, a polycythemia vera (PV) patient and advocate.  In this episode, David shares… The post Pushing for a Diagnosis: A Polycythemia Vera (PV) Story appeared first on The Bloodline with LLS.

Join us as we speak with David Wallace, a polycythemia vera (PV) patient and advocate.  In this episode, David shares… The post Pushing for a Diagnosis: A Polycythemia Vera (PV) Story first appeared on The Bloodline with LLS.

In this episode, Amy E. DeZern, MD, MHS, and Srdan Verstovsek, MD, provide medical oncology and hematology perspectives on new data from ASH 2020 in MDS and MPNs, with topics including:3-year OS results with RIC allogeneic transplantation in patients with higher-risk MDS in the BMT CTN 1102 studyA post hoc analysis of phase II data on the addition of pevonedistat to azacitidine in higher-risk MDS patients5-year results of ropeginterferon α-2b in polycythemia vera from the CONTINUATION-PV studyPhase II results of luspatercept for anemia in patients with myelofibrosis who are transfusion dependentAnalysis of clinical benefit in patients with myelofibrosis and OS benefit from imetelstat.Presenters:Amy E. DeZern, MD, MHSAssociate ProfessorOncology and MedicineThe Johns Hopkins University School of MedicineBaltimore, MarylandSrdan Verstovsek, MD, PhDZProfessorDivision of Cancer MedicineDepartment of LeukemiaThe University of Texas MD Anderson Cancer CenterHouston, TexasContent supported by educational grants from Amgen; AstraZeneca; Bristol-Myers Squibb; Epizyme, Inc; GlaxoSmithKline; Incyte Corporation; Janssen Biotech; Karyopharm Therapeutics Inc; Novartis; PharmaEssentia Corp; Seattle Genetics; and Takeda Oncology.Link to full program and Capsule Summary downloadable slidesets:http://bit.ly/3tyQ9nG

This episode covers polycythemia vera!

Listen to MPN expert Dr. Krisstina Gowin, Assistant professor of medicine in the division of Hematology/Oncology at the university of Arizona Cancer Center, and renowned comic book artist J.G. Jones discuss important topics for those living with an MPN, like the value of education and ways to work with your Healthcare Professional to be an advocate for your health. Dr. Gowin, J.G. Jones, and host, Gina, will also discuss the value of an individualized approach for patients with MPNs.Register now for useful MPN information and resources See the Rare Reflections: MPNs Unmasked series

EHA25 highlights: EHA President John Gribben talks AML, myeloma, polycythemia vera, and COVID-19 What were the late-breaking and practice-changing presentations at EHA25 Virtual? John Gribben, MD, DSc, president of the European Hematology Association, highlighted some of them in this podcast. Dr. Gribben and host David H. Henry, MD, discussed presentations on acute myeloid leukemia (AML), multiple myeloma, polycythemia vera (PV), and COVID-19. Videos of these and other presentations will be available on the EHA25 website until Oct. 15.  Randomized, double-blind, placebo-controlled study of venetoclax with azacitidine vs. azacitidine in treatment-naïve patients with acute myeloid leukemia ineligible for intensive therapy—VIALE-A: Adding venetoclax to azacitidine improved survival, response, and transfusion independence in older patients with treatment-naïve AML.  Older AML patients have seen “very little progress” in outcomes for decades, but advances such as these are “really moving the field,” Dr. Gribben said.  Abstract LB2601: https://rb.gy/fou9jp  Presentation: https://rb.gy/mmwn6s    Phase 2 randomized trial comparing ropeginterferon versus phlebotomy in low-risk patients with polycythemia vera. Results of the pre-planned interim analysis: Ropeginterferon was safe and more effective than phlebotomy for keeping hematocrit on target in patients with low-risk PV.  These findings suggest ropeginterferon is a viable option for PV patients, but “old-fashioned phlebotomy can also be quite efficient,” Dr. Gribben said. Physicians will have to weigh the risks and benefits, including cost-effectiveness, of each treatment, he added. Abstract LB2602: https://rb.gy/uicnmo Presentation: https://rb.gy/sj60ia Isatuximab plus carfilzomib and dexamethasone vs carfilzomib and dexamethasone in relapsed/refractory multiple myeloma (IKEMA): Interim analysis of a phase 3, randomized, open-label study: Adding isatuximab to carfilzomib-dexamethasone improved progression-free survival and time to next treatment. Overall survival data are not mature. The study was stopped early because the primary endpoint was met, as isatuximab “clearly demonstrated superiority,” Dr. Gribben noted. It isn’t clear how isatuximab stacks up against daratumumab, but these results suggest “people now have another CD38 antibody to consider as part of their armamentarium,” Dr. Gribben said.   Abstract LB2603: https://rb.gy/gmxcgk  Presentation: https://rb.gy/v209ol Endotheliopathy in COVID-19 associated coagulopathy   This study showed “very clear evidence” of endothelial damage contributing to coagulopathy among severely ill patients with COVID-19, Dr. Gribben said.  Endothelial cell and platelet markers were elevated in COVID patients who required intensive care, and soluble thrombomodulin was linked to survival.  These findings prompted the decision to give all COVID patients aspirin.  Abstract LB2605: https://rb.gy/sdc9dv  Presentation: https://rb.gy/nxvpxj   Iron metabolism in health and disease (Plenary I)  This presentation suggested inflammation-induced hypoferremia can predict disease severity in COVID-19 patients. The presenter posited that iron accumulation in macrophages may increase inflammation and contribute to organ damage in COVID patients.  “You can imagine a whole cascade of events that this virus triggers off,” Dr. Gribben said. Presentation: https://rb.gy/5lz3d6   Disclosures:   Dr. Gribben reported relationships with Janssen, Celgene, Bristol Myers Squibb, AstraZeneca, AbbVie, Roche, Genentech, and Acerta Pharma.   Dr. Henry reported having no disclosures relevant to this episode.    * * * For more MDedge Podcasts, go to mdedge.com/podcasts Email the show: podcasts@mdedge.com Interact with us on Twitter: @MDedgehemonc David Henry on Twitter: @davidhenrymd  

Hear from an MPN expert—plus a group of real MPN patients! Learn about polycythemia vera, myelofibrosis, and essential thrombocythemia—the rare, chronic blood cancers known as myeloproliferative neoplasms, or MPNs. Listen to Andrea Larson from Incyte Corporation talk with Incyte oncology clinical nurse educator Paul Larson about important topics for people living with MPNs, like tracking symptoms to watch for signs of disease progression. Also hear from Wilma, Marilyn, Dave, and other members of the Voices of MPN community who share their own personal MPN experiences.Learn more about tracking your MPN over time Receive resources to help you better understand and promote awareness of MPNs The content presented in this podcast is not medical advice and should not replace a conversation with your Healthcare Professional, who is the best source of medical information about your individual diagnosis and management plan.

Thank you for joining us for our 2nd Cabral HouseCall of the weekend! I’m looking forward to sharing with you some of our community’s questions that have come in over the past few weeks… Let’s get started!    Alex: Dr. Cabral, thank you so much for your work. The info and protocols you share have literally given me my life back. I listened to your podcast on lectins and need some clarity. The Organic Acids test confirmed some yeast and bacteria overgrowth, and I am currently on month two of the CBO protocol. I did not have any parasites, hpylori or clostridia. I do not want to eat poultry/meat for welfare standard issues, and seafood is not very appetizing to eat (except wild salmon). Thankfully I am not allergic to eggs, so this has been my main source of protein. I noticed the vegan proteins on the sensitive gut guide are mainly legumes. Hemp hearts are great but leave me very hungry in between meals. I have been trying lentils and chickpeas, but still have painful and explosive gas which goes away when I eliminate legumes. I did not have any IGG sensitivities to legumes, but have avoided them for years due to symptoms. Should I rerun the food sensitivity and eat legumes the day before the test? Also, once I complete the CBO protocol would it be possible to digest these vegan legumes? I heard from another source that it's because there is not the bacteria present to breakdown the legumes, but adding certain strains of bacteria can help with digestion. I am wondering if the CBO probiotics will repopulate the gut with these bacteria. Should I try again, is there anything I can do to add these vegan proteins back into my diet or am I just to avoid them for life and occasionally eat poultry/meat to keep protein intake at a decent level? Thanks again Chanel: Dear Dr. Cabral, I am a new listener and have loved every minute. I appreciate your analytical, but practical and caring approach. I also appreciate how you put yourself in the listener’s shoes. Every day, I try to learn more about the microbiome and natural health by reading, listening to podcasts, docuseries, etc. I am writing in to obtain your perspective and guidance. My family and I are on a health journey. We’ve made a lot of changes over the last 1 ½-2 years. I’ve suffered with some health conditions and have made many diet & lifestyle changes in order to improve my health. I still have some things to work on and my goal is to include as many natural/holistic methods as possible in order to regain my health and may write in about my health challenges at a later date. My husband is in the process of making changes too. Most importantly, our three daughters (ages 5, 8 and 12) have been the catalysts for our diet & lifestyle shifts. I am writing in about our girls, primarily my middle daughter. I apologize in advance for the length of this email but will try to condense everything. I’ve been able to look back in hindsight and realize some of the things that brought us to this point. In 2017-2018, we incorporated a lot of wheat in our diet. I thought that was the healthier thing to do so we traded white bread and pasta, etc. for wheat. This, along with an overall less than nutritiously dense diet, regular antibiotic prescriptions, hectic lifestyle, etc. more than likely, contributed to the decline of their gut and digestive health. Our children began to experience many health and digestive issues. Not long after this “wheat swap”, my oldest daughter began to randomly break out in hives. My youngest was diagnosed with GERD and then my middle was diagnosed with GERD along with other conditions. My middle daughter also experienced continuous reflux, stomach pain, bloating, nausea, headaches…you name it! These things heightened last spring; traditional medicine, doctors and specialists were not able to help us and may have set us back with acid blockers. This was a very hard time for our family and for me as a mother as I watched my children suffer. My middle daughter had a feeling of malaise, had low energy and was just not herself. She was also having moments of getting hot/flushed, with rapid heartbeat, headache, stomachache, dizziness, etc. We saw a naturopathic doctor in the spring 2019 and she was very helpful at the time. I also ordered a Diagnostic Solutions GI Map stool test from another practitioner for my middle daughter and the results showed high opportunistic bacteria, extremely low Sec IgA and low normal/”good” bacteria. We were put on a protocol and after treatment, things improved, but my younger two daughters take Miralax to prevent constipation. We removed gluten and dairy and embraced a whole-food, plant-based diet, incorporating organic, grass-fed & finished meats, etc. basically removed most candy & sugar, improved hydration and sleep, as well as slowed down our lifestyle. I thought that we were done with health issues, but my younger two daughters were diagnosed with lichen sclerosis (after many doctor & specialist visits) during the summer of 2019. We recently began seeing another holistic practitioner. She’s been helpful and we’ve incorporated supportive supplements to provide key nutrients that their bodies were missing, as well as some natural based prevention methods. This practitioner uses a Zyto energy scan. I’m skeptical of the scan and don’t fully understand it, but felt it had low risk and low cost so it was worth a try. My daughters and myself had the scan done and the results showed many different types of viruses (to include lyme and co-infections), bacteria, fungi, metals, parasites, microbes, mold, dysbiosis, etc. for all of us. However, my middle daughter is starting to experience some of the same symptoms as last spring, but to a lesser degree. I am very concerned to say the least. I feel that gut & digestive repair is a big piece to this puzzle. She’s had many other symptoms too, such as skin rashes, peeling and itching, an ulcer on her gum, and most recently, we’ve been referred to the children’s orthopedic department for unexplained ankle pain and knee pain that significantly impacts her mobility and to neurology for tingling on the bottom of her feet. I realize that this a lot of information, but I wanted to give you some background on my children. Another MRI was ordered, along with some labs. I’ve ordered your OAT for all of my girls, along with your stool, mold and toxicity tests for my middle daughter. We want to be through and comprehensive in our approach. We don’t want to return to this place of ill-health ever again. I know you can only give advice, but if this were you & your daughters, what would you do? We are desperate to rebalance the body and restore health to my child. We live in a rural community and there are not many practitioners that explore and practice natural-based medicine, along with comprehensive testing. Needless to say, our lives have been disrupted and we’re looking to find a place of peace. I realize you won’t be able to answer this immediately, but wanted your direct feedback.Concerning my middle daughter: *What else could/should we be evaluating or exploring-tests or labs? *What do we do in the meantime while we wait on test results? *Do some of these symptoms sound like an issue with the vagal nerve or gastroparesis? *What are your thoughts on the energy/Zyto Scan? *How would I know if we actually have all of the microbes, infections, bacteria and viruses, etc. reported from the energy scan and the best protocol to treat these things? Where do we start? Please help. Any guidance and/or direction is appreciated. Thank you for your time. ~Chanel Anthony: Hi Dr. Cabral, I’m a big fan and have been listening to you since you were interviewed by the MindPump crew. My wife is in her mid-40’s. She normally has difficulty sleeping however it has gotten worse over the past 6 months. Typically, it lasts around a week and is right before she gets her period. We both believe it is hormonal , common, but not normal. I searched previous podcasts and didn’t find anything. Hoping you can shed some light on the possible etiologies and point is in the right direction. Keep up the great work and thank you for all of the knowledge that you share. Happy Holidays! Anthony Rose: Does too much sugar in older mans diet effect his prostrate levels?? Anonymous: Dr. Cabral, I am writing to let you know that I would love to have you record a follow up to podcast #1306:Mystery Illness Solved:Client Case Study (TWT). My story is similar to your complicated client in that I was diagnosed with a Myeloproliferative cancer in January 2018. I have primary myelofibrosis with a component of Polycythemia Vera (needing an occasional phlebotomy due to hematocrit >45). I also have a history of Hashimotos Thyroiditis (currently on watch and wait) and reflux diagnosed a few years before. I have never had any other health problems in my life andI have been fairly active and healthy. November 2017 when my abnormal bloodwork was found I started an Anti-inflammatory diet and was ultimately able to bring my TPO antibodies from 150 to 70 and heal my reflux. Unfortunately as I continued trying for the next year to heal myself I was not able to improve my blood work with the myelofibrosis. In November 2018 I began working with a Functional Medicine practitioner and he found that I had high levels of mycotoxins, mercury, gut dysbiosis, and parasites. For the next year we worked to resolve and eradicate everything we found with the necessary protocols. I have been dry brushing, juicing, sauna sessions, coffee enemas, DCD, intermittent fasting, weekly 24 hour fast, supplementing, and on a anti-inflammatory diet. I even enrolled in IHP level 1 and 2 in January 2019 in order to further my education. I was trained in conventional medicine as a Physician Assistant and now I feel I could never practice the same way again due to what I have learned in experiencing this health journey. I feel better than I ever have in the past 20 years, the problem is, is that the Myelofibrosis continues to progress and we are at a point where my oncologist is suggesting I need to start on low dose chemotherapy. SO....I would love to hear what you found with your client and how you approached it and your results. I am so thankful for finding you and your wonderful community. Your positive demeanor and messages inspires me in my journey. Thank you for all you do. Rose: Hi, I had my thyroid removed over 25 years ago {goiter growth} I"m on thyroid med. My metabolism is slow. It take my food so long to digest. Im thin 110-115# 66 years. Can you help with this? Thank you   Thank you for tuning into this weekend’s Cabral HouseCalls and be sure to check back tomorrow for our Mindset & Motivation Monday show to get your week started off right! - - - Show Notes & Resources:  http://StephenCabral.com/1430 - - - Dr. Cabral's New Book, The Rain Barrel Effect https://amzn.to/2H0W7Ge - - - Join the Community & Get Your Questions Answered: http://CabralSupportGroup.com - - -   Dr. Cabral’s Most Popular Supplements: > “The Dr. Cabral Daily Protocol” (This is what Dr. Cabral does every day!) - - - > Dr. Cabral Detox  (The fastest way to get well, lose weight, and feel great!) - - - > Daily Nutritional Support Shake  (#1 “All-in-One recommendation in my practice) - - - > Daily Fruit & Vegetables Blend  (22 organic fruit & vegetables “greens powder”) - - - > CBD Oil  (Full-spectrum, 3rd part-tested & organically grown) - - - > Candida/Bacterial Overgrowth, Leaky Gut, Parasite & Speciality Supplement Packages - - - > See All Supplements: https://equilibriumnutrition.com/collections/supplements  - - -   Dr. Cabral’s Most Popular At-Home Lab Tests: > Hair Tissue Mineral Analysis (Test for mineral imbalances & heavy metal toxicity) - - - > Organic Acids Test (Test for 75 biomarkers including yeast & bacterial gut overgrowth, as well as vitamin levels) - - - > Thyroid + Adrenal + Hormone Test  (Discover your complete thyroid, adrenal, hormone, vitamin D & insulin levels) - - - > Adrenal + Hormone Test (Run your adrenal & hormone levels) - - - > Food Sensitivity Test (Find out your hidden food sensitivities) - - - > Omega-3 Test (Discover your levels of inflammation related to your omega-6 to omega-3 levels) - - - > Stool Test (Use this test to uncover any bacterial, h. Pylori, or parasite overgrowth) - - - > Genetic Test (Use the #1 lab test to unlocking your DNA and what it means in terms of wellness, weight loss & anti-aging) - - - > Dr. Cabral’s “Big 5” Lab Tests (This package includes the 5 labs Dr. Cabral recommends all people run in his private practice) - - - > View all Functional Medicine lab tests (View all Functional Medicine lab tests you can do right at home for you and your family)

Take a deep dive into common CBC abnormalities. We recorded LIVE at joint grand rounds between Walter Reed NMMC and Uniformed Services University with hematologist, Dr. Mary Kwok MD. Topics include: which parts of the complete blood count (CBC) are most important, interpreting the differential, when to order flow cytometry, who needs a hematology consult and simplified approaches to patients with leukocytosis, leukopenia, erythrocytosis and thrombocytopenia.  Full show notes at https://thecurbsiders.com/podcast. Join our mailing list and receive a PDF copy of our show notes every Monday. Rate us on iTunes, recommend a guest or topic and give feedback at thecurbsiders@gmail.com. Credits Written, Produced and Edited by: Matthew Watto MD, FACP Cover Art and Infographic by: Matthew Watto MD, FACP Hosts: Stuart Brigham MD; Matthew Watto MD, FACP; Paul Williams MD, FACP Guest: Mary Kwok MD   Sign Up for a course w/our Chief of POCUS, Dr. Renee Dversdal! ACP - acponline.org/pocus AIUM - Check out https://aium.org for upcoming events.  TRUST (Train the Ultrasound Trainers) https://www.ultrasoundtraining.com.au/courses/category/train-the-ultrasound-trainer-trust Time Stamps 00:00 Intro; Paul shame’s the audience; Guest bio 03:17 Guest one-liner, book recommendation* -Emperor of All Maladies (book) by Siddhartha Mukherjee, When Breath Becomes Air (book) by Paul Kalanithi; Career advice -set goals for whatever you’re learning. 08:43 Picks of the week: John Wick 3 (film); The Movies That Made Me (podcast) by Joe Dante; The Tim Ferriss Podcast with Julie Rice of Soul Cycle; Infinity Chamber (film) by Travis Milloy 11:50 A case of asymptomatic leukocytosis; Red flags; Repeat the CBC until it’s normal 17:30 The peripheral smear; Leukemoid reaction 20:00 The physical exam; When to send flow cytometry? 22:18 A case of lymphopenia; benign ethnic neutropenia; What to look for in the history 27:10 A case of erythrocytosis; Checking EPO levels; JAK2 mutation; Differential Diagnosis; Therapeutic Phlebotomy; Physical findings of Polycythemia Vera 36:53 A case of thrombocytopenia; Lab workup; Differential diagnosis; Pathophysiology; Culprit meds 45:35 Advice for internists 46:36 Take Home Points 47:46 Dr. Kwok’s disclaimer 48:10 Outro and post credit scene

MPN Chronicles Podcast – 04, PV Reporter, Always Ask Your Doctor for your CBC or your test results and keep a binder to Monitor your Progress by David Wallace After 2 visits to the ER, I finally had my first hematologist meeting.  She reviewed the tests that were done in the ER and ran a […]

MPN Chronicles Podcast – 04, PV Reporter, Always Ask Your Doctor for your CBC or your test results and keep a binder to Monitor your Progress by David Wallace After 2 visits to the ER, I finally had my first hematologist meeting.  She reviewed the tests that were done in the ER and ran a […]

Only about 14,500 people in the U.S. will be diagnosed with an MPN this year, and the number for polycythemia vera, a type of MPN, is even less—about 22 cases per 100,000 people. On this episode of Frankly Speaking About Cancer, we'll learn more about polycythemia vera, as well as tips for managing a rare cancer.